Rhabdoid Tumor

22 registered clinical trials studyying Rhabdoid Tumor — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors NCT06625190	University of Florida	Phase 1 / Phase 2
Recruiting	Study to ONO-4538 in Patients With Rhabdoid Tumor NCT06622941	Ono Pharmaceutical Co., Ltd.	Phase 2
Withdrawn	Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant NCT05952687	St. Jude Children's Research Hospital	Phase 1
Recruiting	A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors NCT05985161	Memorial Sloan Kettering Cancer Center	Phase 2
Active Not Recruiting	Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors NCT05286801	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 NCT04897321	St. Jude Children's Research Hospital	Phase 1
Active Not Recruiting	B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT04483778	Seattle Children's Hospital	Phase 1
Completed	Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels NCT04537715	Epizyme, Inc.	Phase 1
Active Not Recruiting	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT03618381	Seattle Children's Hospital	Phase 1
Active Not Recruiting	Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors NCT03709680	Pfizer	Phase 2
Terminated	A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT NCT04897880	Australian & New Zealand Children's Haematology/Oncology Group	Phase 2
Completed	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678	National Cancer Institute (NCI)	Phase 2
Completed	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665	National Cancer Institute (NCI)	Phase 2
Completed	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035	National Cancer Institute (NCI)	Phase 2
Completed	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620	National Cancer Institute (NCI)	Phase 2
Terminated	Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms T NCT02581384	Dana-Farber Cancer Institute	Phase 1 / Phase 2
Completed	Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors NCT02390843	Emory University	Phase 1
Completed	A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory S NCT01625351	St. Jude Children's Research Hospital	Phase 1
Completed	Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors NCT01331135	Emory University	Phase 1
Completed	Collecting and Storing Tissue From Young Patients With Cancer NCT00898755	Children's Oncology Group	—
Completed	Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors NCT00179803	Ann & Robert H Lurie Children's Hospital of Chicago	Phase 2